Cas No.: | 610318-03-1 |
Chemical Name: | RGX-104 HCl |
Synonyms: | RGX-104 hydrochloride; RGX-104 HCl; RGX-104; RGX104; RGX 104; SB742881; SB-742881; SB 742881; |
SMILES: | C[C@H](CCOC1=CC=CC(=C1)CC(=O)O)N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4.Cl |
Formula: | C34H34Cl2F3NO3 |
M.Wt: | 632.56 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. |
In Vivo: | Oral administration of GW3965 or RGX-104 to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Strong tumor growth suppression is also observed in animals bearing large tumors. In some instances, the treatment causes partial or complete tumor regression. Responses are seen across a wide spectrum of malignancies, including lung cancer, melanoma, glioblastoma, and ovarian, renal cell, triple-negative breast, and colon cancer[1]. |